Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

152
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
152
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

121
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
121
Sign Test for Matched Pairs01:17

Sign Test for Matched Pairs

104
The sign test for matched pairs offers a robust method for comparing two paired samples, often for the effects of an intervention in one of them. This method is very useful in situations where the underlying distribution of the data is unknown. The test compares two related samples—often pre- and post-treatment measurements on the same subjects—to determine if there are significant differences in their median values.
To conduct the sign test, we first calculate the differences in...
104
Behrens–Fisher Test00:57

Behrens–Fisher Test

66
The Behrens-Fisher test is a statistical method designed to address the Behrens-Fisher problem, which arises when comparing the means of two normally distributed populations with unequal variances. Unlike the Student's t-test, which assumes equal variances, the Behrens-Fisher test allows for mean comparison without this restrictive assumption. This flexibility makes it particularly valuable in scenarios where two independent samples exhibit normality but lack variance homogeneity.
This test...
66
Bonferroni Test01:10

Bonferroni Test

2.7K
The Bonferroni test is a statistical test named after Carlo Emilio Bonferroni, an Italian mathematician best known for Bonferroni inequalities. This statistical test is a type of multiple comparison test to determine which means are different than the rest. Bonferroni test can minimize the Type 1 error by reducing the significance level alpha, which otherwise increases with sample pairs.
The means of different samples are first paired in all possible combinations.
The null hypothesis of the...
2.7K
Strategies for Assessing and Addressing Confounding01:25

Strategies for Assessing and Addressing Confounding

83
Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
83

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

CUI-MET: A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple-Dose, Multiple-Outcome Randomized Trials.

Pharmaceutical statistics·2026
Same author

Corrigendum to "A clinical rule-based indicator to identify recurrence of colorectal cancer after curative resection using linked routinely collected national data" [Cancer Epidemiol. 100 (2026) 102962].

Cancer epidemiology·2026
Same author

Statistical Guardrails for Hybrid-Controlled Trials: Robust to Confounding and Between-Study Heterogeneity.

Therapeutic innovation & regulatory science·2026
Same author

A clinical rule-based indicator to identify recurrence of colorectal cancer after curative resection using linked routinely collected national data.

Cancer epidemiology·2025
Same author

Efficacy of Individual-Level Interventions to Mitigate the Risk for Burnout Among Health Care Professionals : A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Annals of internal medicine·2025
Same author

Cure Models: What is Meant by a Survival 'Plateau', and Do Experts Agree on What Constitutes One?

PharmacoEconomics·2025
Same journal

Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control.

Pharmaceutical statistics·2026
Same journal

Harmonic Fowlkes-Mallows Index for Medical Diagnostics Tests and Optimal Cut-Off Point Selection of Binary Diseases.

Pharmaceutical statistics·2026
Same journal

Early Phase Dose-Finding Designs for CAR-T Cell Therapies.

Pharmaceutical statistics·2026
Same journal

Optimizing Randomization Ratios in Clinical Trials With Survival Endpoints.

Pharmaceutical statistics·2026
Same journal

Will the Pharmaceutical Industry Need Statisticians in an AI World?

Pharmaceutical statistics·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2025

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.4K

Bayesian Solutions for Assessing Differential Effects in Biomarker Positive and Negative Subgroups.

Dan Jackson1, Fanni Zhang2, Carl-Fredrik Burman3

  • 1Statistical Innovation, AstraZeneca, Cambridge, UK.

Pharmaceutical Statistics
|November 26, 2024
PubMed
Summary
This summary is machine-generated.

Bayesian methods help personalize medicine by analyzing clinical trials with biomarkers. These methods aid decisions on drug approval and trial design for biomarker-positive and -negative subgroups.

Keywords:
informative prior distributionsmedical decision makingprior sensitivitysubgroup analysis

More Related Videos

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

15.6K
Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers
03:37

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Published on: March 1, 2024

641

Related Experiment Videos

Last Updated: Jun 6, 2025

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.4K
Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

15.6K
Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers
03:37

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Published on: March 1, 2024

641

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Personalized Medicine

Background:

  • The rise of personalized medicine has increased clinical trials using binary biomarkers.
  • Drugs may show differential efficacy in biomarker-positive versus all-comer populations, posing challenges for medical decision-makers.

Purpose of the Study:

  • To develop and evaluate Bayesian methods for assessing treatment efficacy in biomarker-defined subgroups.
  • To provide tools for medical decision-making regarding drug approval and clinical trial design.

Main Methods:

  • Development of Bayesian statistical models based on a common data model.
  • Proposal of diverse prior specifications to represent varying prior knowledge on subgroup treatment effects.
  • Illustration with real-world clinical trial examples.

Main Results:

  • Demonstration of the utility of Bayesian methods in evaluating subgroup-specific treatment effects.
  • Application of the methodology to inform decisions on treatment recommendation in biomarker-negative subgroups.
  • Guidance on determining optimal patient numbers for biomarker-positive and -negative groups in trial design.

Conclusions:

  • Bayesian framework offers a natural approach for complex decision-making in biomarker-driven clinical trials.
  • The methods support decisions on drug approval and optimizing clinical trial design for personalized medicine.